PURPOSE: To examine the rate of timely postpartum screening for diabetes among Medicaid-eligible women with gestational diabetes mellitus (GDM). METHODS: We examined a retrospective cohort of Medicaid women with a live birth between 2004 and 2007. Women with singleton live births at greater than 28 weeks gestation were included in the cohort and their screening receipt tracked. Only the first qualifying pregnancy within the observation period was assessed. Birth certificate records were linked with hospital discharge data, outpatient prenatal care claims to identify women with GDM (n = 6,239). Medicaid postpartum claims for these women were examined to determine receipt of postpartum screening for diabetes within 5 to 13 weeks. Women with any indication of a dedicated plasma glucose test identified by CPT codes 82947, 82950, 82951, and 82952 during this time period were considered to meet the definition of screening. RESULTS: Approximately 3.4% of women identified as having GDM were screened for diabetes postpartum. Adjusted analysis found women not attending the postpartum visit (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.37-0.91) and women receiving inadequate prenatal care (OR, 0.57; 95% CI, 0.34-0.95) were less likely to receive postpartum screening for diabetes. Conversely, women 20 to 34 years of age (OR, 1.79; 95% CI, 1.21-2.66) and women who were obese (OR, 2.28; 95% CI, 1.56-3.32) were more likely to be screened. CONCLUSIONS: Medicaid is a primary source of insurance for many women; however, for most coverage ends at 60 days postpartum, leaving a narrow window of opportunity for postpartum screening. Extended periods of coverage may be beneficial in ensuring the opportunity to receive adequate postpartum care, including screening for diabetes.
PURPOSE: To examine the rate of timely postpartum screening for diabetes among Medicaid-eligible women with gestational diabetes mellitus (GDM). METHODS: We examined a retrospective cohort of Medicaid women with a live birth between 2004 and 2007. Women with singleton live births at greater than 28 weeks gestation were included in the cohort and their screening receipt tracked. Only the first qualifying pregnancy within the observation period was assessed. Birth certificate records were linked with hospital discharge data, outpatient prenatal care claims to identify women with GDM (n = 6,239). Medicaid postpartum claims for these women were examined to determine receipt of postpartum screening for diabetes within 5 to 13 weeks. Women with any indication of a dedicated plasma glucose test identified by CPT codes 82947, 82950, 82951, and 82952 during this time period were considered to meet the definition of screening. RESULTS: Approximately 3.4% of women identified as having GDM were screened for diabetes postpartum. Adjusted analysis found women not attending the postpartum visit (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.37-0.91) and women receiving inadequate prenatal care (OR, 0.57; 95% CI, 0.34-0.95) were less likely to receive postpartum screening for diabetes. Conversely, women 20 to 34 years of age (OR, 1.79; 95% CI, 1.21-2.66) and women who were obese (OR, 2.28; 95% CI, 1.56-3.32) were more likely to be screened. CONCLUSIONS: Medicaid is a primary source of insurance for many women; however, for most coverage ends at 60 days postpartum, leaving a narrow window of opportunity for postpartum screening. Extended periods of coverage may be beneficial in ensuring the opportunity to receive adequate postpartum care, including screening for diabetes.
Authors: Hannah R Lucas; Roxann C Williams; Laura N Hollar; Bethany Johnson-Javois; Heidi B Miller; Amanda Stoermer; Graham A Colditz; Aimee S James; Cynthia J Herrick Journal: Clin Diabetes Date: 2022-01
Authors: Thaddeus P Waters; Shin Y Kim; Andrea J Sharma; Pamela Schnellinger; Janet K Bobo; Robert T Woodruff; Lisa A Cubbins; Mary Haghiac; Judi Minium; Larraine Presley; Honor Wolfe; Sylvie Hauguel-de Mouzon; William Adams; Patrick M Catalano Journal: Diabetologia Date: 2019-12-09 Impact factor: 10.122
Authors: Cynthia J Herrick; Matthew R Keller; Anne M Trolard; Ben P Cooper; Margaret A Olsen; Graham A Colditz Journal: Am J Prev Med Date: 2020-12-11 Impact factor: 5.043
Authors: Judith A Bernstein; Lois McCloskey; Christina M Gebel; Ronald E Iverson; Aviva Lee-Parritz Journal: BMJ Open Diabetes Res Care Date: 2016-06-17